ATE66673T1 - 2-pyrrolidonderivate, verfahren zur herstellung, pharmazeutische zusammensetzungen und anwendung. - Google Patents

2-pyrrolidonderivate, verfahren zur herstellung, pharmazeutische zusammensetzungen und anwendung.

Info

Publication number
ATE66673T1
ATE66673T1 AT86106249T AT86106249T ATE66673T1 AT E66673 T1 ATE66673 T1 AT E66673T1 AT 86106249 T AT86106249 T AT 86106249T AT 86106249 T AT86106249 T AT 86106249T AT E66673 T1 ATE66673 T1 AT E66673T1
Authority
AT
Austria
Prior art keywords
preparation
application
pharmaceutical compositions
pyrrolidone derivatives
alkylene
Prior art date
Application number
AT86106249T
Other languages
English (en)
Inventor
Hironori Ikuta
Youji Yamagishi
Kozo Akasaka
Isao Yamatsu
Seiichi Kobayashi
Hiroshi Shirota
Kouichi Katayama
Original Assignee
Eisai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai Co Ltd filed Critical Eisai Co Ltd
Application granted granted Critical
Publication of ATE66673T1 publication Critical patent/ATE66673T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24Oxygen or sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36Oxygen or sulfur atoms
    • C07D207/382-Pyrrolones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24Oxygen or sulfur atoms
    • C07D207/262-Pyrrolidones
    • C07D207/2632-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C07D207/272-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/50Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572Five-membered rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pain & Pain Management (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Pyrrole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Cosmetics (AREA)
AT86106249T 1985-05-09 1986-05-07 2-pyrrolidonderivate, verfahren zur herstellung, pharmazeutische zusammensetzungen und anwendung. ATE66673T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP60096799A JPH066571B2 (ja) 1985-05-09 1985-05-09 2−ピロリドン誘導体

Publications (1)

Publication Number Publication Date
ATE66673T1 true ATE66673T1 (de) 1991-09-15

Family

ID=14174668

Family Applications (1)

Application Number Title Priority Date Filing Date
AT86106249T ATE66673T1 (de) 1985-05-09 1986-05-07 2-pyrrolidonderivate, verfahren zur herstellung, pharmazeutische zusammensetzungen und anwendung.

Country Status (19)

Country Link
US (1) US4833160A (de)
EP (1) EP0204964B1 (de)
JP (1) JPH066571B2 (de)
KR (1) KR910004789B1 (de)
CN (1) CN1014058B (de)
AT (1) ATE66673T1 (de)
AU (1) AU581078B2 (de)
CA (1) CA1264762A (de)
DE (1) DE3681076D1 (de)
DK (1) DK213286A (de)
ES (1) ES8800148A1 (de)
FI (1) FI84172C (de)
HU (2) HU199117B (de)
MX (1) MX162717A (de)
NO (1) NO861820L (de)
NZ (1) NZ216092A (de)
PH (2) PH23189A (de)
PT (1) PT82540B (de)
ZA (1) ZA863352B (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5356917A (en) * 1985-08-09 1994-10-18 Eli Lilly And Company Aryl-substituted rhodanine derivatives
US5691367A (en) * 1985-08-09 1997-11-25 Eli Lilly And Company Aryl-substituted rhodanine derivatives
US5202341A (en) * 1987-03-11 1993-04-13 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Hydroxystyrene compounds having tyrosine kinase inhibiting activity
US5089516A (en) * 1987-03-11 1992-02-18 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha 1-phenyl-3,5-pyrazolidinedione hydroxystyrene compounds which have tyrosine kinase inhibiting activity
WO1988007035A1 (en) * 1987-03-11 1988-09-22 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Hydroxystyrene derivatives
US5216002A (en) * 1989-12-21 1993-06-01 Eli Lilly And Company Method of treating inflammatory bowel disease
US5143928A (en) * 1990-03-27 1992-09-01 Warner-Lambert Company 3,5-di-tertiarybutyl-4-hydroxyphenylmethylene derivatives of 2-substituted thiazolidinones, oxazolidinones, and imidazolidinones as antiinflammatory agents
DE69221794T2 (de) * 1991-01-21 1998-03-19 Shionogi Seiyaku Kk 3-benzyliden-1-carbamoyl-2-pyrrolidon-analoga
EP0532767B1 (de) * 1991-04-05 1997-03-05 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha 3-Phenoxybenzyl(iden)pyrrolidin-Derivate, deren Herstellung und deren Verwendung als muskarin-cholinerge Mittel
AU675078B2 (en) * 1992-10-28 1997-01-23 Shionogi & Co., Ltd. Benzylidene derivatives
US5358964A (en) * 1993-07-26 1994-10-25 Warner-Lambert Company Benzylidene-lactone and their thiocarbonyl analogs as inhibitors of proteoglycan degradation
GB9704499D0 (en) * 1997-03-05 1997-04-23 Glaxo Wellcome Spa Method of manufacture
CN103342672B (zh) * 2013-07-02 2015-12-23 扬州大学 取代吡咯烷-2-酮的新合成方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3714153A (en) * 1970-06-22 1973-01-30 Roussel Uclaf Novel cyclopropanecarboxylic acids
DE2329308A1 (de) * 1972-03-03 1975-01-02 Gruenenthal Chemie Neue lactame
AU518986B2 (en) * 1977-10-11 1981-10-29 Takeda Chemical Industries Ltd. Lactams
US4138495A (en) * 1978-05-19 1979-02-06 Stauffer Chemical Company N-Substituted pyrrolidones and their use as miticides
US4431656A (en) * 1981-02-05 1984-02-14 Kanegafuchi Chemical Industry Company Limited 3,5-di-Tert-butylstyrene derivatives, salts thereof, and pharmaceutical compositions containing the same as an active ingredient
US4440784A (en) * 1981-02-05 1984-04-03 Kanegafuchi Chemical Industry Company, Ltd. Anti-inflammatory, analgesic, and antipyretic pharmaceutical composition
JPS57130950A (en) * 1981-02-05 1982-08-13 Kanegafuchi Chem Ind Co Ltd 3,5-di-tert-butyl-4-hydroxystyrene derivative and anti- inflammatory, analgesic, antipyretic agent and inhibitor for blood platelet aggregation
JPS5879944A (ja) * 1981-11-09 1983-05-13 Kanegafuchi Chem Ind Co Ltd 3,5−ジ・タ−シヤリ−・ブチルスチレン誘導体及び抗炎症、鎮痛、解熱剤並びに血小板凝集阻害剤
DE3326724A1 (de) * 1983-07-25 1985-02-07 Boehringer Ingelheim KG, 6507 Ingelheim In 1-stellung substituierte 4-hydroxymethyl-pyrrolidinone, verfahren zu ihrer herstellung, pharmazeutische zusammensetzungen und zwischenprodukte
JPS6112660A (ja) * 1984-06-27 1986-01-21 Kanegafuchi Chem Ind Co Ltd 新規2−ピロリドン誘導体及び抗炎症剤
JPH0623194B2 (ja) * 1985-03-23 1994-03-30 鐘淵化学工業株式会社 新規ラクタム誘導体及び抗炎症剤
JPS6412660A (en) * 1987-07-07 1989-01-17 Canon Kk Original reader
JP3611676B2 (ja) * 1996-06-24 2005-01-19 アサマ化成株式会社 パン生地の改良剤およびパンの製造方法

Also Published As

Publication number Publication date
NZ216092A (en) 1988-08-30
MX162717A (es) 1991-02-18
ZA863352B (en) 1986-12-30
HU196749B (en) 1989-01-30
KR910004789B1 (ko) 1991-07-13
HUT45493A (en) 1988-07-28
PH23225A (en) 1989-06-06
NO861820L (no) 1986-11-10
PH23189A (en) 1989-05-29
HUT43040A (en) 1987-09-28
EP0204964B1 (de) 1991-08-28
CA1264762A (en) 1990-01-23
ES8800148A1 (es) 1987-11-01
PT82540A (en) 1986-06-01
FI84172C (fi) 1991-10-25
JPS61257967A (ja) 1986-11-15
HU199117B (en) 1990-01-29
FI861698A (fi) 1986-11-10
DK213286D0 (da) 1986-05-07
JPH066571B2 (ja) 1994-01-26
CN1014058B (zh) 1991-09-25
CN86103227A (zh) 1987-01-21
PT82540B (pt) 1988-08-17
KR860008973A (ko) 1986-12-19
ES554775A0 (es) 1987-11-01
DK213286A (da) 1986-11-10
AU581078B2 (en) 1989-02-09
AU5676686A (en) 1986-11-13
US4833160A (en) 1989-05-23
FI861698A0 (fi) 1986-04-22
DE3681076D1 (de) 1991-10-02
EP0204964A1 (de) 1986-12-17
FI84172B (fi) 1991-07-15

Similar Documents

Publication Publication Date Title
ATE66673T1 (de) 2-pyrrolidonderivate, verfahren zur herstellung, pharmazeutische zusammensetzungen und anwendung.
PT584347E (pt) Compostos de xantina hidroxilados enantiomericos
IE940525L (en) Known and selected novel arylmethylenyl derivatives of¹thiazolidinones, imidazolidinones and oxazolidinones useful¹as antiallergy agents and antiinflammatory agents
PT92153A (pt) Processo para a preparacao de derivados de 1,4-diazepina e de composicoes farmaceuticas que os contem
NZ240230A (en) Mercaptoacetylamide derivatives; preparation, use and pharmaceutical compositions thereof
ES2174298T3 (es) Derivados de aminotiazol, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
FI944823A0 (fi) Galantamiinijohdannaisia, menetelmä niiden valmistamiseksi ja niiden käyttö lääkeaineissa
EA199801028A1 (ru) Применение производных п-аминофенола для проготовления фармацевтических композиций, используемых при лечении нейродегенеративных заболеваний
UA49005C2 (uk) Похідні камптотецину (варіанти), спосіб їх одержання (варіанти) та фармацевтична композиція на їх основі
DK0736029T3 (da) Antikonvulsive pseudofructopyranosesulfamater
MD502G2 (ro) Derivaţi noi ai adenozinei, procedee de preparare a lor, compoziţii farmaceutice ce le conţin
EE04058B1 (et) Benso[c]kinolisiini derivaadid, nende valmistamine ja kasutamine 5a-reduktaasi inhibiitoritena
NO903430L (no) Fremgangsmaate for fremstilling av aminoketonderivater.
FR2687154B1 (fr) Nouveau derive de l'isoindolinone, sa preparation et les compositions pharmaceutiques qui le contiennent.
ATE96152T1 (de) 2-methylthiomethyl-dihydropyridine, verfahren zur herstellung und pharmazeutische zusammenstellungen, die sie enthalten.
ES2012567A6 (es) Procedimiento de preparacion de derivados de quinolinio e isoquinolinio condensados.
ATE228359T1 (de) Hemmung der leukotrienbiosynthese mittels harnstoffderivaten
EP0826663A3 (de) Alkynylaminosäure Derivate und ihre Verwendung als pharmazeutische Verbindungen